HIV
Treatment-as-prevention (HPTN 052), universal ART (START), U=U (PARTNER) and long-acting injectable PrEP (HPTN 083).
- Trials
- 4
- Years
- 2011–2021
Sort
- 2021HPTN 083Long-acting PrEPIn 4,566 cisgender MSM and transgender women at high risk of HIV, long-acting injectable cabotegravir every 8 weeks reduced HIV acquisition compared with daily oral TDF/FTC.HR 0.34Read →
- 2019PARTNER / PARTNER2U=UIn ≥1,000 serodifferent couples, HIV transmission during condomless sex when the HIV+ partner had viral load <200 copies/mL produced zero phylogenetically linked transmissions across ≥76,000 condomless sex acts.Read →
- 2015START CoreUniversal early ARTIn 4,684 ART-naïve adults with CD4 >500/µL, immediate antiretroviral therapy reduced serious AIDS and non-AIDS events compared with deferred ART.HR 0.43Read →
- 2011HPTN 052 CoreTreatment as preventionIn 1,763 HIV-serodiscordant couples, early antiretroviral therapy of the HIV-positive partner reduced linked HIV transmission compared with delayed ART.Read →